Search

Your search keyword '"Barda, Noam"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Barda, Noam" Remove constraint Author: "Barda, Noam" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
155 results on '"Barda, Noam"'

Search Results

1. Bridging the gap: Towards an Expanded Toolkit for AI-driven Decision-Making in the Public Sector

3. SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023

6. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

7. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

15. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines

19. Corrigendum to 'Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up', Clinical Microbiology and Infection Volume 29, Issue 7, July 2023, Pages 918-923

24. Corrigendum to "Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" [Clin Microbiol Infect] 29 (7) (2023) 918–923.

25. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel

26. Bridging the Gap: Towards an Expanded Toolkit for ML-Supported Decision-Making in the Public Sector

30. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose

31. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

32. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

33. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up

34. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

35. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

37. Chronic health conditions among long‐term survivors of adolescent and young adult cancer: A comparison of outcomes in Israel and the United States.

44. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)

45. Correlates of Protection of BNT162b2 Against COVID-19 Infection and Intensity of Symptomatic Disease; the Israeli COVID-19 Family Study (ICoFS)

46. Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 Outcomes – A Retrospective Cohort Study ​

50. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Catalog

Books, media, physical & digital resources